Exhibit 99.1 MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand EscharEx® Phase III study preparations progressing; Protocol submission to FDA expected in first quarter 2024 Cash of $46 million; Operating cash runway through profitability Conference call on Tuesday, November 21 at 8:30 a.m. Eastern Time YAVNE, Israel, November 21, 2023 -- MediWound Ltd. ...